January 04, 2013 Friday - updated 13:00 PM PT

MissionIR News – Cardium Therapeutics, Inc. (CXM) to Increase Excellagen Clinical Adoption by U.S. Government Medical Providers via New Distribution Agreement

Atlanta, United States (IBwire.com - January 04, 2013) MissionIR would like to highlight Cardium Therapeutics, Inc. (NYSE MKT: CXM), an asset-based, health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative products and businesses with the potential to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the newly-acquired To Go Brands nutraceutical supplement business.

In the company’s news yesterday,

Cardium Therapeutics announced it has entered a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals.

An FDA-cleared gel, Excellagen is used to support advanced wound care in a broad range of dermal wounds. Academy Medical’s will initially focus on providing education and training on the use of Excellagen in the treatment of traumatic wounds, non-healing venous, pressure and diabetic ulcers, limb salvage, and post-Mohs skin cancer surgery, while supporting distribution within its growing customer base of over 35 VA and military hospitals within the U.S.

The VA operates the nation’s largest integrated healthcare system. With a healthcare budget of over $50 billion, VA has estimated more than 6.0 million patients were provided with care during over 900,000 inpatient hospital admissions and nearly 80 million outpatient visits during 2012. VA’s healthcare network includes 152 major medical centers and more than 800 community-based outpatient clinics.

“As the U.S. healthcare market continues to expand due to the aging population and with the implementation of the Affordable Care Act, simpler-use and more cost-effective medical products like Excellagen have an opportunity to expand and grow within outcomes-oriented healthcare settings,” commented Christopher J. Reinhard, Chairman and CEO of Cardium. “Our agreement with Academy Medical expands Cardium’s tactical access and distribution capabilities for Excellagen as we advance forward with our planned U.S. strategic partnering activities. We are in discussions with potential strategic partners to establish representation, marketing and sales, or co-promotional arrangements along four U.S. vertical wound healing market channels: (1) podiatry, (2) wound care centers, hospitals, and long-term care facilities, (3) government medical service providers; and (4) dermatology.”

There have been important, positive findings reported by physicians using Excellagen. To review case studies, visit www.excellagen.com/surgical-wounds.html.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

 

Media Contact:

Senior Editor
MissionIR
Communications
3645 Marketplace Blvd.
Atlanta, GA

Phone: 404-941-8975
Email: editor@missionir.com
Website: www.missionir.com
img_submit
creat you account

Terms of Service | Privacy Policy | Link to IBwire | Contact Us

Issuers of press releases and not IBwire are only accountable for the precision of the information they included.
If you have any inquiries or questions concerning the press release please contact the company directly listed in the press release.

© Copyright 2014, IBwire inc

submit press release | press release distribution | press release service